StoxNephrocare Health Services Limited
NSE: NEPHROPLUS · Healthcare
Ask the data
Instant answers about Nephrocare Health Services Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 998.9 |
| EBITDA | 227.0 |
| Operating margin | 22.7% |
| Interest | 60.2 |
| Depreciation | 90.7 |
| Profit before tax | 100.6 |
| Tax | 20.6 |
| Net profit | 76.8 |
| EPS ₹ | 8.48 |
| Operating cash flow | 232.6 |
| Capex | 119.4 |
| Dividend paid | 0.0 |
| Total assets | 1,470.9 |
| Equity | 1,116.5 |
Quarterly performance
last 4 quarters · ₹ crore| DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|
| Revenue | 259.7 | 265.6 | 281.8 | 303.4 |
| Operating profit | 60.9 | 53.8 | 63.9 | 67.1 |
| Operating margin | 23.4% | 20.2% | 22.7% | 22.1% |
| Other income | 3.3 | 11.6 | 7.5 | 8.0 |
| Interest | 6.0 | 3.2 | 2.2 | 3.1 |
| Depreciation | 21.9 | 25.8 | 24.5 | 27.7 |
| Profit before tax | 36.4 | 36.3 | 44.6 | 44.3 |
| Tax | 4.1 | 2.9 | 9.1 | 6.9 |
| Net profit | 32.2 | 30.4 | 32.0 | 33.5 |
| EPS ₹ | 3.43 | 3.03 | 3.19 | 3.34 |
Returns & margins
trailing-twelve-month, per quarter| SEP '26 | |
|---|---|
| ROE | 10.8% |
| ROCE | 13.9% |
| Net margin | 11.5% |
| EBITDA margin | 22.1% |
| Debt / equity | 0.07 |
| Interest coverage | 12.18 |
| Asset turnover | 0.68 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '26 | SEP '26 | |
|---|---|---|
| Share capital | 20.1 | 20.1 |
| Other equity / reserves | 1,096.4 | 1,168.9 |
| Total equity | 1,116.5 | 1,189.0 |
| Borrowings | 79.7 | 79.5 |
| Current liabilities | 299.4 | 378.8 |
| Non-current liabilities | 55.0 | 65.6 |
| Total assets | 1,470.9 | 1,633.3 |
| Property, plant & equipment | 396.2 | 347.7 |
| Capital work-in-progress | 5.5 | 7.1 |
| Investments | 177.8 | 213.6 |
| Inventories | 33.0 | 47.4 |
| Receivables | 316.9 | 327.5 |
| Cash & equivalents | 123.9 | 213.2 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | 232.6 |
| Cash from investing | -410.4 |
| Cash from financing | 157.1 |
| Capex | 119.4 |
| Free cash flow | 113.2 |
| Dividends paid | 0.0 |
Where the assets sit
Sep '26 · ₹ crorePeer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Nephrocare Health Services Limited | 6,051 | 601.75 | 47.2 | 5.09 | 10.8% |
StoxGud checklist: Neutral setup · 4/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Nephrocare Health Services Limited?
Nephrocare Health Services Limited (NEPHROPLUS) closed at ₹601.75 on NSE on 06 Nov 2026.
What is the market cap of Nephrocare Health Services Limited?
₹6,051 crore at the latest close.
What is the P/E ratio of Nephrocare Health Services Limited?
47.2, on trailing-twelve-month earnings from its filings.
How fast is Nephrocare Health Services Limited growing?
Not enough filed history yet to measure Nephrocare Health Services Limited's growth.
How profitable is Nephrocare Health Services Limited?
On a trailing-twelve-month basis return on equity is 10.8%, return on capital employed 13.9%, operating margin 22.1%, net margin 11.5%.
How much debt does Nephrocare Health Services Limited have?
Nephrocare Health Services Limited is lightly geared: debt to equity is 0.07 with borrowings of ₹80 cr against cash of ₹213 cr (balance sheet of 2026-09-30). Operating profit covers interest 12.2 times.
Financials parsed from Nephrocare Health Services Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from DEC '25, annual from FY26, balance sheet from Mar '26. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.